Is ACL overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for ACL, then validate with fundamentals and peer multiples.
Australian Clinical Labs Limited (ACL) is currently Undervalued by 37.22%
Instant valuation answer
Australian Clinical Labs Limited (ACL) appears undervalued by approximately 37.22% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 37.22% (from live valuation API)
- Confidence (live) 8/10 (High)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$2.96
Explore Our Valuation Calculators
Why is Australian Clinical Labs Limited overvalued or undervalued?
For Australian Clinical Labs Limited, intrinsic value ties fair value to sustainable cash generation; with the stock below that level, the snapshot reads as a discount versus fundamentals rather than a pure sentiment call.
Historical valuation for ACL shows cycles where multiples expanded and compressed; today’s positioning rhymes more with defensive pricing than the mid-range of its recent history.
Market expectations boil down to growth, risk, and return on capital—current levels leave more room for upside if execution is steady. Cross-check with live ratios when your API is connected.
Key metrics
- P/E ratio
- 40.4x
- Revenue growth (TTM y/y)
- 27%
- Profit margin
- 17.3%
- Fair value (model)
- Unlock
Frequently asked questions — ACL
What is Australian Clinical Labs Limited's intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether ACL trades above or below fair value. At $2.96, Australian Clinical Labs Limited currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Australian Clinical Labs Limited's intrinsic value calculated?
Tickerplace calculates ACL's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is ACL undervalued right now?
Based on our 2026 valuation models, Australian Clinical Labs Limited (ACL) appears undervalued at $2.96 with about 37.2% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.